	US 12,454,573 B2
	Dosages of emactuzumab
Raymond Barlow, Dublin (IE); Axel Mescheder, Dublin (IE); Michael Cannarile, Penzberg (DE); and Georgina Meneses-Lorente, Welwyn Garden City (GB)
Assigned to SYNOX THERAPEUTICS UK LIMITED, Oxford (GB)
Filed by Synox Therapeutics UK Limited, Oxford (GB)
Filed on Nov. 1, 2022, as Appl. No. 18/051,816.
Claims priority of provisional application 63/274,634, filed on Nov. 2, 2021.
Prior Publication US 2023/0340110 A1, Oct. 26, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); A61K 2039/545 (2013.01)]

5 Claims

1. A method for the treatment of tenosynovial giant cell tumour (TGCT) in a subject, according to a treatment regimen;

wherein the treatment regimen consists of five treatment cycles of Emactuzumab; and,

wherein a treatment cycle comprises one administration of about 1000 mg of Emactuzumab; and

wherein the administration is an intravenous (IV) administration.